Stock listing

BOATS:KALV KalVista Pharmaceuticals, Inc. Stock

US listing (BOATS) of KalVista Pharmaceuticals, Inc. · home listing NASDAQ:KALV

Follow KalVista Pharmaceuticals, Inc. into a list and get an email when it puts out news.

KalVista Pharmaceuticals, Inc. logo
Ticker
BOATS:KALV
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All KalVista Pharmaceuticals, Inc. news

KalVista Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
15 in the last 12 months · 164 in all · newest Nov 12, 2026 · oldest 2019
Calls
2 calls with a replay · 2 with a transcript · latest Nov 11, 2025
Decks
17 decks · latest October 2026

Where KalVista Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KALV · Home listingNASDAQUnited StatesUSD
gettex:4XC1gettexGermanyEUR
LS Exchange:A2DG49LS ExchangeGermanyEUR
Tradegate:4XC1TradegateGermanyEUR
BOATS:KALV · This pageBOATSUnited StatesUSD
Lang & Schwarz:A2DG49Lang & SchwarzGermanyEUR
Frankfurt:4XC1FrankfurtGermanyEUR
Munich:4XC1MunichGermanyEUR
Dusseldorf:4XC1DusseldorfGermanyEUR
Hamburg:4XC1HamburgGermanyEUR
Stuttgart:4XC1StuttgartGermanyEUR

Team and board

Officers

OfficerRole
Bilal ArifChief Operating Officer
Jeb LedellChief Operating Officer
Leah MonteiroSenior Director, Corporate Communications & Investor Relations
Molly CameronSr. Director, Corporate Communications
Ryan BakerHead, Investor Relations
Jenn SnyderVice President, Corporate Affairs

Board

DirectorRole
Bethany L. SensenigDirector
Laurence ReidDirector

Events

Open Events

Decks

DeckKindSlidesDate
2026 HAEi Regional Conference AmericasConference11 slidesOctober 2026
Investor Presentation (January 2026)Investor deck20 slidesJan 8, 2026
Q2 2025 Earnings PresentationEarnings19 slidesSep 11, 2025
Corporate Update (July 2025)Corporate update24 slidesJul 7, 2025
Technical Presentation (May 2025)Technical11 slidesMay 2025
Technical Presentation (May 2025)Technical11 slidesMay 2025
Bradykinin Symposium 2024Conference13 slidesSeptember 2024
Technical Presentation (September 2024)Technical11 slidesSeptember 2024
Technical Presentation (May 2024)Technical16 slidesMay 31, 2024
Investor Presentation (February 2024)Investor deck32 slidesFeb 13, 2024
All 17 decks
DeckKindSlidesDate
Technical Presentation (2024)Technical11 slides2024
Technical Presentation (2024)Technical11 slides2024
Technical Presentation (May 2023)Technical13 slidesMay 2023
Technical Presentation (May 2023)Technical14 slidesMay 2023
HAEi Global Leadership Workshop, Frankfurt, October 6-9, 2022Conference13 slidesOctober 2022
EAACI 2022Conference12 slidesJul 1, 2022
Investor Presentation (July 2018)Investor deck36 slidesJul 31, 2018

Open Decks

Financings

RaiseDate
Convertible notes
Closed: US$144M raised
Use of proceeds: Continue advancing the global launch strategy for EKTERLY and building long-term growth
Nov 10, 2025
Convertible Senior Notes due 2031
Announced: US$110M
Use of proceeds: Working capital and general corporate purposes, including the commercialization of EKTERLY; possibly investments in or acquisitions of other companies or products
Sep 24, 2025

Open Financings · Read by 6ix AI from the company's releases

Shareholders

Funds

HolderSharesValueAs of
The Arbitrage Fund691KUS$18.6MMay 31, 2026
Emerald Growth Fund260KUS$6.93MApr 30, 2026
BlackRock Health Sciences Opportunities Portfolio213KUS$5.71MMay 29, 2026
Fidelity Extended Market Index Fund204KUS$5.49MMay 31, 2026
Vanguard Russell 2000 Index Fund197KUS$5.29MMay 31, 2026
Schwab U.S. Small-Cap ETF190KUS$5.11MMay 31, 2026
AltShares Merger Arbitrage ETF90,263US$2.43MMay 31, 2026
Vanguard Health Care Index Fund82,908US$2.23MMay 31, 2026
iShares ESG Aware MSCI USA Small-Cap ETF76,735US$2.06MMay 31, 2026
Fidelity Total Market Index Fund74,994US$2.02MMay 31, 2026
All 36 holders
HolderSharesValueAs of
Fidelity Series Total Market Index Fund60,035US$1.61MMay 31, 2026
ALPS Medical Breakthroughs ETF52,105US$1.4MMay 31, 2026
Water Island Event-Driven Fund37,497US$1.01MMay 31, 2026
Vanguard Russell 2000 Growth Index Fund36,056US$969KMay 31, 2026
Fidelity Nasdaq Composite Index Fund31,757US$853KMay 31, 2026
Fidelity Nasdaq Composite Index ETF30,371US$816KMay 31, 2026
Schwab U.S. Broad Market ETF23,406US$629KMay 31, 2026
Small Cap Index Fund15,296US$411KMay 31, 2026
ProShares Merger ETF13,850US$372KMay 31, 2026
AltShares Event-Driven ETF9,139US$246KMay 31, 2026
Invesco NASDAQ Future Gen 200 ETF4,724US$127KMay 31, 2026
Siit Extended Market Index Fund4,700US$126KMay 31, 2026
AQR Small Cap Momentum Style Fund3,609US$72,649Mar 31, 2026
Vanguard Russell 3000 Index Fund3,117US$83,754May 31, 2026
Federated Hermes Global Allocation Fund2,767US$74,349May 31, 2026
Invesco Nasdaq Biotechnology ETF2,736US$73,516May 31, 2026
iShares MSCI World Small-Cap ETF1,996US$53,633May 31, 2026
ProShares Ultra Nasdaq Biotechnology1,870US$50,247May 31, 2026
ProShares Russell 2000 High Income ETF1,806US$48,527May 31, 2026
Columbia Integrated Small Cap Growth Fund1,793US$48,178May 31, 2026
ProShares UltraPro Russell20001,429US$38,397May 31, 2026
ProShares Ultra Russell20001,412US$37,940May 31, 2026
Morgan Stanley Pathway Small-Mid Cap Equity ETF1,301US$34,958May 31, 2026
Destinations Small-Mid Cap Equity Fund1,162US$31,223May 31, 2026
ProShares Hedge Replication ETF36US$967May 31, 2026
ProShares Russell 2000 Dynamic Buffer ETF12US$322May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Yea Christopher
Officer: CHIEF DEVELOPMENT OFFICER
Sale33,800USD 26.78US$905KMay 27, 2026
Yea Christopher
Officer: CHIEF DEVELOPMENT OFFICER
Sale1,966USD 26.78US$52,649May 26, 2026
Sweeny Nicole
Officer: Chief Commercial Officer
Sale1,489USD 26.78US$39,875May 26, 2026
Audhya Paul K.
Officer: CHIEF MEDICAL OFFICER
Sale2,239USD 26.78US$59,960May 26, 2026
Palleiko Benjamin L
Director, Officer: CHIEF EXECUTIVE OFFICER
Sale10,926USD 26.78US$293KMay 22, 2026
Yea Christopher
Officer: CHIEF DEVELOPMENT OFFICER
Sale2,358USD 26.78US$63,147May 22, 2026
Piekos Brian
Officer: Chief Financial Officer
Sale1,489USD 26.78US$39,875May 22, 2026
Sweeny Nicole
Officer: Chief Commercial Officer
Sale1,861USD 26.78US$49,838May 22, 2026
Audhya Paul K.
Officer: CHIEF MEDICAL OFFICER
Sale2,685USD 26.78US$71,904May 22, 2026
Palleiko Benjamin L
Director, Officer: CHIEF EXECUTIVE OFFICER
Sale1,129USD 26.76US$30,212May 18, 2026
All 17 trades
TradeTradeSharesPriceValueDate
Yea Christopher
Officer: CHIEF DEVELOPMENT OFFICER
Sale1,108USD 26.76US$29,650May 18, 2026
Audhya Paul K.
Officer: CHIEF MEDICAL OFFICER
Sale1,032USD 26.76US$27,616May 18, 2026
Palleiko Benjamin L
Director, Officer: CHIEF EXECUTIVE OFFICER
Sale3,322USD 26.71US$88,731May 12, 2026
Palleiko Benjamin L
Director, Officer: CHIEF EXECUTIVE OFFICER
Sale9,550USD 20.22US$193KApr 17, 2026
Piekos Brian
Officer: Chief Financial Officer
Sale1,862USD 20.22US$37,650Apr 17, 2026
Sweeny Nicole
Officer: Chief Commercial Officer
Sale1,862USD 20.22US$37,650Apr 17, 2026
Audhya Paul K.
Officer: CHIEF MEDICAL OFFICER
Sale2,686USD 20.22US$54,311Apr 17, 2026

Big stakes

StakeStakeSharesDateFiling
Capital World Investors6.40%3.18MMar 31, 2025Schedule 13G
Silverarc Capital Management, LLC5.60%2.88MMar 31, 2026Schedule 13G
Frazier Life Sciences Public Fund, L.P.2.30%1.25MMay 19, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Nov 21, 2016 – Oct 12, 2017 · Past
William C. Fairey
Other companies: Ascendis Pharma A/S (Director · Since at least Mar 18, 2026); Rein Therapeutics, Inc. (Director · Since at least Oct 31, 2023); Mirum Pharmaceuticals, Inc. (Director · Since at least Aug 19, 2021); MyoKardia Inc (EVP, Chief Commercial Officer · Jan 28, 2019 – Nov 17, 2020 · Past); ChemoCentryx Inc. (Chief Operating Officer · Jan 3, 2018 – Jan 3, 2018 · Past)
Director · Since at least Apr 18, 2024
Albert Cha
Other companies: Ascendis Pharma A/S (Chairman · Since at least Mar 18, 2026); Biohaven Pharmaceutical Holding Co Ltd (Director · May 3, 2017 – May 1, 2018 · Past); Aclaris Therapeutics, Inc. (Director · Oct 6, 2015 – Jun 29, 2016 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past)
Director · Mar 23, 2017 – Sep 26, 2023 · Past
Richard Aldrich
Other companies: Concert Pharmaceuticals Inc (Director · Feb 12, 2014 – Mar 6, 2023 · Past); PTC Therapeutics, Inc. (Director · Mar 7, 2013 – Jun 8, 2015 · Past); Tempest Therapeutics, Inc. (Director · Jun 11, 2012 – Dec 7, 2018 · Past); Verastem, Inc. (Director · Jan 26, 2012 – Jun 10, 2014 · Past)
Director · Nov 21, 2016 – Oct 3, 2018 · Past
Bilal Arif
Other companies: Sarepta Therapeutics, Inc. (Chief Tech Ops Officer · Since at least Dec 31, 2022)
Chief Operating Officer · Since at least Oct 6, 2025
Brian J. G. Pereira
Other companies: ProKidney Corp. (Director · Since at least May 30, 2024)
Director · Since at least Oct 3, 2024
Nancy Stuart
Other companies: Concert Pharmaceuticals Inc (Chief Operating Officer · Jan 6, 2023 – Mar 6, 2023 · Past)
Director · Since at least Oct 13, 2022
Nicole Sweeny
Other companies: Monopar Therapeutics Inc. (Board Member · Since at least Jun 22, 2026)
Chief Commercial Officer · Since at least Jun 18, 2025
Benjamin L PalleikoCHIEF EXECUTIVE OFFICER, Director · Since at least Apr 16, 2026
Bethany L. SensenigDirector · Since at least Oct 2, 2025
All 21 people
PersonSeat
Christopher YeaCHIEF DEVELOPMENT OFFICER · Since at least May 17, 2025
Edward W UnkartDirector · Since at least Mar 23, 2017
Jeb LedellChief Operating Officer · Since at least Dec 16, 2024
Jenn SnyderVice President, Corporate Affairs · Since at least Feb 10, 2025
Laurence ReidDirector · Since at least Nov 26, 2024
Leah MonteiroSenior Director, Corporate Communications & Investor Relations · Since at least Feb 3, 2026
Michael David SmithSenior VP, Development · Dec 16, 2020 – May 17, 2022 · Past
Molly CameronSr. Director, Corporate Communications · Since at least Apr 8, 2026
Paul K AudhyaCHIEF MEDICAL OFFICER · Since at least May 17, 2025
Ryan BakerHead, Investor Relations · Since at least Apr 29, 2026
Thomas Andrew CrockettCEO, Director · Jun 4, 2018 – Feb 17, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about KalVista Pharmaceuticals, Inc.